Loss of RASSF2 Enhances Tumorigencity of Lung Cancer Cells and Confers Resistance to Chemotherapy
Figure 6
Inactivation of RASSF2 confers resistance to cisplatin and taxol. H441 cells stably transfected with control and RASSF2 shRNA constructs were seeded at 2 × 104 cells per well in 12-well plates and treated with 5 nM taxol or 10 μM cisplatin for 3 days. Cell death was estimated by trypan blue exclusion. Cells stably transfected with the RASSF2 shRNA showed significantly less cell death () compared to the control cells for both taxol and cisplatin treatments.
